Navigation Links
SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
Date:4/7/2008

DUBLIN, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that multiple abstracts have been accepted for oral and poster presentations at the AACR Annual Meeting, which will take place April 12-16 in San Diego, California.

An oral presentation by Dr. Steven Warner will highlight SuperGen's PIM Kinase Inhibitor in cell lines from hematological and solid malignancies. The poster presentations will focus on data concerning many of SuperGen's current oncology programs, including the lead clinical compound, MP-470, and its ability to suppress the repair of double stranded DNA breaks following treatment with DNA-damaging agents.
SuperGen's schedule of presentations is as follows:

Date Time (PDT) Abstract # and Title

Sunday, 8 a.m. - 12 p.m. #671 -- Inhibition of erlotinib resistance

April 13 on HER-family tyrosine kinases by

combination with MP-470, a

multi-targeted TK inhibitor in prostate and

breast cancer

Monday, 1 p.m. - 5 p.m. #2613 -- The dinucleotide prodrug of

April 14 decitabine demonstrated increased in vivo

efficacy due to enhanced drug delivery and

stability

Tuesday, 8 a.m. - noon #4083 -- MP-470, a potent oral Rad51

April 15 suppressor is safe and tolerable in

first-in-human study

Tuesday, 2:25 p.m. - #4974 -- A potent small molecule PIM kinase

April 15 2:40 p.m. inhibitor with activity in cell lines from

(oral presentation) hematological and solid malignancies

Tuesday, 1 p.m. - 5 p.m. #4891 -- Activity of the multi-targeted,

April 15 receptor tyrosine kinase inhibitor MP-470

against synovial sarcoma cells

Wednesday, 8 a.m. - noon #5729 -- Pharmacokinetics of MP-529, a

April 16 selective Aurora A kinase inhibitor, in a

novel subcutaneous delivery system

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications Manager, Investor Relations

& Business Development

Tel: (925) 560-0100 Tel: (925) 560-2845

E-mail: tenns@supergen.com E-mail: mary.vegh@supergen.com


'/>"/>
SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
2. Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization
3. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
4. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
5. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
6. Mayo Clinic Proceedings Contributors Highlight Research Findings About Cardiovascular Benefits Associated With Omega-3 Fatty Acids
7. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
8. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
9. Mitchell, Military TBI Task Force Highlight the Importance of Traumatic Brain Injury Research; Mitchell Endorses Ground Breaking Traumatic Brain Injury Study
10. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
11. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , Feb. 20, 2017   Orion Health ... its Amadeus precision medicine platform to the ... currently manages over 110 million patient records globally. ... developing cloud-based, big data solutions built on modern, scalable ... Healthcare and Life Sciences. "The AWS Cloud gives healthcare ...
(Date:2/20/2017)... , Feb. 20, 2017 Seal Shield ... health IT solution for mobile device management and disinfection, ... HIMSS Conference and Exhibition in Orlando, Fla. ... Mobile devices have become commonplace in today,s ... a new set of concerns, including the disinfection and ...
(Date:2/20/2017)... Feb. 20, 2017  There has been a paradigm ... (NCDs) across sub-Saharan Africa, which in turn is driving ... of more Western lifestyle diseases such as cardiovascular disease ... infectious and parasitic illness, will present the pharmaceutical industry ... opportunity of $40.8 billion in 2019. "An ...
Breaking Medicine Technology:
(Date:2/20/2017)... PA (PRWEB) , ... February 20, 2017 , ... ... collaborating to help health care providers better manage patient health risks, foster behavior change ... medication video library in the world, will present a demonstration of its video capability ...
(Date:2/20/2017)... TX (PRWEB) , ... February 20, 2017 , ... ... is now offering a full range of emergency dental care at his office, ... and gums. When patients experience dental emergencies, they are at risk for serious ...
(Date:2/19/2017)... ... February 19, 2017 , ... The Citadel’s new Swain ... is being led by Amelia Joseph, Ph.D. Joseph was engaged by the college as ... nursing department in early 2016. After a nation-wide search, she was selected to head ...
(Date:2/18/2017)... (PRWEB) , ... February 17, ... ... Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, ... Are manufacturers looking to reduce their regulatory burden? Pay dividends in enhanced ...
(Date:2/18/2017)... ... February 18, 2017 , ... ... Use Pixel Film Studios ’ ProParagraph Fashion Volume 2 for all multi-line ... other applications. Users can pick and choose from hand-crafted trend-setting designs with ...
Breaking Medicine News(10 mins):